stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) Book value per share
Jazz Pharmaceuticals PLC's book value per share at the end of fiscal 2025 was 70.8×, up 6.97% from 66.2× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 64.8×. Over the past ten years it has ranged from 26.1× (fiscal 2015) to 70.8× (fiscal 2025) — the current reading is the highest in ten years. Jazz Pharmaceuticals PLC ranks 10th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 70.8× | 6.97% |
| FY2024 | 66.2× | 12.12% |
| FY2023 | 59.0× | 19.67% |
| FY2022 | 49.3× | (25.72%) |
| FY2021 | 66.4× | 1.12% |
| FY2020 | 65.7× | 19.83% |
| FY2019 | 54.8× | 19.24% |
| FY2018 | 46.0× | 1.70% |
| FY2017 | 45.2× | 45.68% |
| FY2016 | 31.0× | 18.85% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 64.8× | (14.73%) |
| Jun 2026 | 76.0× | 3.76% |
| Mar 2026 | 73.2× | 3.39% |
| Dec 2025 | 70.8× | 8.58% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC | 64.8× |
| BMRN BioMarin Pharmaceutical Inc. compare | 32.3× |
| ASND Ascendis Pharma A/S compare | 26.0× |
| KYMR Kymera Therapeutics, Inc. compare | 16.1× |
| TECH Bio-Techne Corp compare | 13.5× |
| EXEL Exelixis, Inc. compare | 7.4× |
| SMMT Summit Therapeutics PLC compare | 0.8× |
| HALO Halozyme Therapeutics, Inc. compare | −0.5× |
| BBIO BridgeBio Pharma, Inc. compare | −8.4× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on JAZZ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement